Drug intelligence / Profile preview

Navatac Gyno

Development stage: Unknown
Lead developer: Meditrina Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Navatac Gyno is a multi-ingredient food supplement and medical food developed by MEDITRINA Pharmaceuticals, specifically formulated for the management of nausea, vomiting, and retching during pregnancy, as well as motion sickness. Launched in early 2018, the product contains a combination of vitamin B6 (pyridoxine), ginger extract, artichoke extract, alginic acid, calcium carbonate, and potassium bicarbonate. Its mechanism of action involves the antiemetic properties of ginger and vitamin B6, digestive support from artichoke extract, and the neutralization of gastric acidity through alginic acid and bicarbonates. It is administered orally in tablet form.

Brand names: Navatac Gyno
Other names: Navatac

Targets

HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on Navatac Gyno.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navatac Gyno.

Explore the full profile